Avinger (NASDAQ:AVGR) Receives New Coverage from Analysts at StockNews.com

Analysts at StockNews.com initiated coverage on shares of Avinger (NASDAQ:AVGR) in a note issued to investors on Wednesday. The brokerage set a “hold” rating on the medical device company’s stock.

Separately, HC Wainwright reiterated a “buy” rating and issued a $5.00 target price on shares of Avinger in a research note on Thursday, March 21st.

Avinger Stock Performance

Shares of AVGR stock opened at $1.94 on Wednesday. The company has a market capitalization of $3.30 million, a price-to-earnings ratio of -0.11 and a beta of 1.12. Avinger has a 52-week low of $1.59 and a 52-week high of $18.00. The company has a 50-day simple moving average of $3.09 and a two-hundred day simple moving average of $3.07.

Avinger (NASDAQ:AVGR) last announced its quarterly earnings data on Wednesday, May 15th. The medical device company reported ($2.49) earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of ($1.35) by ($1.14). The business had revenue of $1.86 million during the quarter, compared to analysts’ expectations of $2.36 million. On average, sell-side analysts forecast that Avinger will post -2.08 EPS for the current fiscal year.

About Avinger

Avinger, Inc, a commercial-stage medical device company, designs, manufactures, and sells a suite of image-guided and catheter-based systems used by physicians to treat patients with peripheral artery disease (PAD) primarily in the United States and Germany. The company develops lumivascular platform that integrates optical coherence tomography visualization with interventional catheters to provide real-time intravascular imaging during the treatment portion of PAD procedures.